Joe Copia's daytrades/investments and thoughts Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Joe Copia's daytrades/investments and thoughts

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Joe Copia who wrote (22858)	7/26/2000 2:55:51 PM
From: paper man	Read Replies (1) of 25711

Joe - alert:serious events unfolding in HIV treatments: AIDS Treatment Activists Call for Fast Track Development of Reticulose WEDNESDAY, JULY 26, 2000 1:31:00 PM EST NEW YORK, Jul 26, 2000 /PRNewswire via COMTEX/ -- With the close of the 13th International AIDS Conference, a coalition of leading AIDS Treatment activists are demanding better access to Reticulose, a lipoprotein-nucleic acid complex manufactured by Advanced Viral Research that has shown promise in the treatment of many of the symptoms of HIV disease. Reticulose is presently available through a compassionate use program approved by the FDA, but many activists are claiming this is not enough. "Many people presently receiving Reticulose through the compassionate access program are doing better but there are hundreds of thousands of people living with AIDS who need access to this promising therapy but can't receive it," said David Miller, Director of Brooklyn Medical Arts AIDS CARE Center and a member of ACT UP Brooklyn. "We are urging Advanced Viral Research to peruse federal clinical research and to apply for fast track designation at the FDA to accelerate access for the thousands that are intolerant to the side effects of antiviral therapy." Jeannie Gibbs, a veteran AIDS treatment activist now working with the International HIV IBT Working Group is petitioning FDA officials and legislators to move aggressively to ensure access to Reticulose. "I'm confident we're going to secure the necessary support to encourage the development of Reticulose in the next few weeks." Advanced Viral Research is presently pursuing mature discussions with leading clinical research organizations including Anderson Clinical Research Institute who will be retained to execute trials in HIV patients during the next two to three months. Sources close to the company revealed that dramatic in vitro results of a study analyzing the potential of Reticulose for the treatment of HIV will be submitted for presentation during the 38th annual meeting of the Infectious Disease Society of America taking place September 7-10, 2000 in New Orleans, LA. SOURCE Brooklyn Medical Arts AIDS CARE Center CONTACT:David Miller, 718-222-4600 or Jeannie Gibbs, both of Brooklyn Medial Arts AIDS CARE Center prnewswire.com (C) 2000 PR Newswire. All rights reserved. KEYWORD:New York INDUSTRY KEYWORD: MTC HEA

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next